1. Home
  2. BNR vs UNCY Comparison

BNR vs UNCY Comparison

Compare BNR & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$20.08

Market Cap

216.9M

Sector

Health Care

ML Signal

HOLD

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

HOLD

Current Price

$5.59

Market Cap

126.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNR
UNCY
Founded
2014
2016
Country
China
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
216.9M
126.4M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
BNR
UNCY
Price
$20.08
$5.59
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$44.50
AVG Volume (30 Days)
53.2K
360.0K
Earning Date
11-20-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$75,749,382.00
N/A
Revenue This Year
$136.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.56
N/A
52 Week Low
$2.18
$3.71
52 Week High
$24.48
$11.00

Technical Indicators

Market Signals
Indicator
BNR
UNCY
Relative Strength Index (RSI) 50.64 46.20
Support Level $19.59 $5.36
Resistance Level $21.07 $5.95
Average True Range (ATR) 2.23 0.33
MACD -0.15 -0.06
Stochastic Oscillator 39.11 23.16

Price Performance

Historical Comparison
BNR
UNCY

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Share on Social Networks: